This study is looking at how Ramipril, a medication, might improve walking ability in people with peripheral arterial disease (PAD). PAD causes narrowing of arteries, leading to claudication (leg pain when walking that goes away with rest). Researchers want to understand why Ramipril helps by looking at changes in muscle and blood vessels in the leg. You might be able to join if you are between 18 and 90 years old, have chronic claudication, and have arterial occlusive disease confirmed by tests. The study will give Ramipril, starting at a low dose and increasing to 10mg/day for 22 weeks. Success will be measured by how far you can walk at 6 months. The current status of this study is unclear.

Study design

This is an interventional study with a planned enrollment of 70 participants. It will test the effects of Ramipril.

What's involved

Participants will take Ramipril daily for 24 weeks, with the dose gradually increasing over the first three weeks. Walking ability will be measured at 6 months.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, Absolute Claudication Distance, is measured at 6 months, indicating follow-up for at least this duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.